Phosphagenics, Nippon Zoki Pharmaceuticals Co. Ltd. deal

Following a March 2012 evaluation deal, the companies partnered to develop Phosphagenics' topical TPM/diclofenac to treat acute and chronic pain in the U.S. The companies partnered last year to allow Nippon to evaluate the product to treat pain. Nippon Zoki markets topical diclofenac products that do not use the TPM delivery system in Japan. Phosphagenics, which said the license is still being negotiated, said it will be eligible for milestones, plus royalties (see BioCentury, March 12, 2012). ...